Molbio Diagnostics Share Price Target Rs 1,600: Stock Jumps 5% as HDFC Mutual Fund Buys 1.99% in Bulk Deal

Molbio Diagnostics is a Goa-based point-of-care diagnostics company whose Truenat platform tests for more than 30 diseases. The Molbio Diagnostics stock has had a volatile run since listing at Rs 980 on 17 August against an IPO price of Rs 807. It climbed to a 52-week high of Rs 1,686.80, fell about 26% to Rs 1,255.60 by 29 September, and then drew fresh buyers through a bulk deal and a Jefferies Buy rating.

If you are searching for the Molbio Diagnostics share price target or the reason behind today's move, this article covers the Molbio Diagnostics bulk deal in which HDFC Mutual Fund bought from Business Excellence Trust III, a Motilal Oswal Alternates vehicle, what Jefferies expects through operating leverage, how Molbio earns revenue, and the key risks. Price data is based on NSE and BSE figures, so recheck it before acting.

Click Here – Get Free Investment Predictions

Why Did Molbio Diagnostics Share Price Rise Today?

The Molbio Diagnostics share price rose because HDFC Mutual Fund emerged as the main buyer in a bulk deal that moved about 2% of the company between large holders. HDFC Mutual Fund picked up 23 lakh shares at Rs 1,315, while Business Excellence Trust III sold 23.28 lakh shares in a deal worth about Rs 306 crore.

A fresh 1.99% stake from a mutual fund signals a longer holding view, since funds usually build positions with months or years in mind. It also absorbs a block of supply that could have weighed on the Molbio Diagnostics share price. The overhang has not fully cleared, though: this was the second sale by the same seller in recent days, after a 2.6% stake sale for about Rs 394 crore a week earlier.

Bulk Deal Behind the Molbio Diagnostics Share Price Jump

Parameter	Details
Company (NSE: MOLBIO, BSE: 544866)	Molbio Diagnostics
Buyer	HDFC Mutual Fund (about 1.99% stake)
Seller	Business Excellence Trust III (Motilal Oswal Alternates)
Shares bought and sold	23 lakh bought by HDFC Mutual Fund; 23.28 lakh sold by the seller
Deal price	Rs 1,315 per share
Deal value	About Rs 306 crore
Earlier sale by the seller	2.6% stake for about Rs 394 crore a week before

The deal price of Rs 1,315 sits about 4.7% above the 29 September close of Rs 1,255.60, which suggests the buyer paid up for a large block instead of waiting for a dip.

What Is a Bulk Deal and Why Does It Matter for Molbio Diagnostics Stock?

A bulk deal is a trade in which the quantity bought or sold in a single day exceeds 0.5% of a company's listed shares, and the exchanges publish the names of the buyer and seller. Investors track a Molbio Diagnostics bulk deal because it shows who is accumulating and who is exiting.

The deal here had HDFC Mutual Fund as buyer and Business Excellence Trust III as seller. Disclosures like this let retail investors see where large money is moving, but a single trade does not decide the Molbio Diagnostics share price.

Jefferies Buy Call: Molbio Diagnostics Share Price Target Rs 1,600

Jefferies initiated coverage with a Buy rating and a Rs 1,600 target, naming Molbio its high-conviction pick in Indian medical devices and supplies. That target implies about 27% upside from the 29 September close of Rs 1,255.60 and sits nearly 98% above the Rs 807 IPO price. The call sent the stock up about 9% in the 30 September session, which set the stage for the move in the Molbio Diagnostics share price on 1 October.

Jefferies estimate	Figure
Revenue CAGR, FY26 to FY29E	22%
Profit after tax CAGR, FY26 to FY29E	47%
EBITDA CAGR, FY26 to FY29E	36%
Margin expansion	About 830 basis points
Test-kit capacity utilisation	58% in FY26 to 77% by FY29E
Optrascan share of sales	11% by FY29E

The thesis rests on operating leverage. If more Truenat test kits run through existing capacity, costs fall as a share of sales. That would support the Molbio Diagnostics share price through earnings growing at more than twice the pace of revenue, which is what a 47% profit CAGR against a 22% revenue CAGR implies.

Check the Univest Screener for live data on healthcare and diagnostics stocks

What Is Molbio Diagnostics and How Does It Make Money?

Molbio Diagnostics is a Goa-based point-of-care diagnostics company founded in 2000, best known for its portable Truenat molecular testing platform, which covers more than 30 diseases. Newer offerings include Prorad and Optrascan, which Jefferies expects to widen the revenue base. Those products matter for the Molbio Diagnostics share price because they reduce reliance on test kits.

Test kits made up 73.98% of FY26 sales, devices 14.53% and exports 9.6%. The company sold 2,524 Truenat devices and 1.76 crore test kits in FY26, up from 2,180 devices and 1.22 crore kits in FY25.

Financials (Rs crore)	FY24	FY25	FY26
Revenue from operations	836.56	1,020.42	1,445.69
Profit after tax	83.54	138.58	164.14

The momentum carried into Q1 FY27. The company reported a consolidated profit of Rs 52.74 crore on 7 September, against a loss of Rs 23.94 crore a year earlier, with total income rising to Rs 411.48 crore from Rs 100.47 crore. That helps explain why the Molbio Diagnostics share price has held well above its issue price.

Download the Univest iOS App or Univest Android App to track live prices of healthcare and diagnostics stocks.

Molbio Diagnostics Share Price Since the IPO: From Rs 807 to Rs 1,686

Molbio Diagnostics share price milestone	Price	Detail
IPO price	Rs 807	Band Rs 768 to Rs 807, issue size about Rs 939.70 crore, subscribed 70.26 times
Listing, 17 August	Rs 980	21.44% premium to the issue price
Post-listing high	Rs 1,686.80	About 109% above the issue price
29 September close	Rs 1,255.60	About 26% below the high, 56% above the issue price
Bulk deal price	Rs 1,315	HDFC Mutual Fund purchase
Jefferies target	Rs 1,600	Buy rating, initiated on 30 September
1 October	Up over 5%	About 71% above the issue price

The path has been volatile. The Molbio Diagnostics share price hit a 20% upper circuit on 10 September and then gave back about a quarter of its peak value within weeks, typical of a recently listed stock with active sellers.

Risks to Watch in the Molbio Diagnostics Share Price

Rich valuation: At about Rs 1,320 on 23 September, the Molbio Diagnostics share price traded near 89 times trailing earnings, so the market already expects much of the growth Jefferies projects.

Continued selling by early investors: The Rs 739.70 crore offer for sale in the issue was entirely existing holders exiting, and Business Excellence Trust III has now sold twice in recent days. Further block sales could cap rallies in the Molbio Diagnostics share price.

Product concentration: Test kits contributed nearly 74% of FY26 sales, so demand for Truenat kits drives results, and the Molbio Diagnostics share price, more than any other line.

Price volatility: A 20% upper circuit followed by a 26% fall from the high within weeks shows how quickly sentiment can swing in the Molbio Diagnostics stock.

What Could Move the Molbio Diagnostics Share Price Next?

Watch four things: further block deals, since fresh institutional buying would reinforce the HDFC Mutual Fund signal; the Q2 FY27 results for margin and kit volume trends; traction in Prorad and Optrascan; and whether the stock can hold above the Rs 1,315 deal price. Holding that level is the first test for the Molbio Diagnostics share price on the way toward the Rs 1,600 target.

Conclusion

The Molbio Diagnostics share price has picked up two supports in two days: a Buy rating with a Rs 1,600 target from Jefferies and a Rs 306 crore block purchase by HDFC Mutual Fund at Rs 1,315. Against that, the Molbio Diagnostics stock trades near 89 times earnings and early investors are still selling. The Rs 1,315 deal price and the Rs 1,686.80 post-listing high frame the next move. Consult a SEBI-registered advisor before making any decision.

Frequently Asked Questions

Why did Molbio Diagnostics share price rise today?

Ans. Molbio Diagnostics shares rose over 5% on 1 October after HDFC Mutual Fund bought about 1.99% of the company in a bulk deal at Rs 1,315 per share. The buying follows a Jefferies Buy initiation with a Rs 1,600 target, which put the Molbio Diagnostics share price in focus.

Who bought and who sold in the Molbio Diagnostics bulk deal?

Ans. HDFC Mutual Fund bought about 23 lakh shares, and Business Excellence Trust III, a vehicle of Motilal Oswal Alternates, sold 23.28 lakh shares. The deal was worth about Rs 306 crore at Rs 1,315 per share. The purchase coincided with a jump in the Molbio Diagnostics share price.

What is the Molbio Diagnostics share price target by Jefferies?

Ans. Jefferies has a Buy rating on Molbio Diagnostics with a target price of Rs 1,600, about 27% above the 29 September close of Rs 1,255.60. These are broker estimates, not guaranteed returns.

What was the Molbio Diagnostics IPO price and listing price?

Ans. The Molbio Diagnostics IPO was priced at Rs 807 per share within a band of Rs 768 to Rs 807. The shares listed on 17 August at Rs 980, a 21.44% premium to the issue price.

Is Molbio Diagnostics a good stock to buy now?

Ans. This article does not constitute investment advice. The stock has strong growth estimates and fresh mutual fund buying, but the Molbio Diagnostics share price trades near 89 times earnings and early investors have been selling heavily. Consult a SEBI-registered financial advisor before investing.

What does Molbio Diagnostics do?

Ans. Molbio Diagnostics is a Goa-based point-of-care diagnostics company known for its portable Truenat molecular testing platform, which tests for more than 30 diseases. It is also building newer products such as Prorad and Optrascan.

What is the post-listing high of Molbio Diagnostics share price?

Ans. The stock hit a post-listing high of Rs 1,686.80, then fell about 26% to close at Rs 1,255.60 on 29 September.

What could push Molbio Diagnostics share price toward Rs 1,600?

Ans. Further institutional buying, healthy Q2 FY27 results, rising test-kit capacity utilisation and traction in new products are the main triggers for the Molbio Diagnostics share price. These are factors to watch, not guaranteed outcomes.